TCGA-69-7978-01A-11R-2187-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 59
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.944 |
| 2 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.903 |
| 3 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.895 |
| 4 | 6bf9821d-da67-470f-9650-69d05b056166 | — | — | 0.894 |
| 5 | TCGA-55-6971-01A-11R-1949-07 | — | cohortMD2 | 0.889 |
| 6 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.886 |
| 7 | SRR10900557 | — | — | 0.885 |
| 8 | SRR5088879 | — | — | 0.885 |
| 9 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.885 |
| 10 | d719788d-0c64-4488-bb84-ab5536d31a03 | — | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |